Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP05: Perioperative Dietary Therapy in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Michel Adamina
Created: Tuesday, 23 June 2020, 5:40 PM
DOP05: Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Elisa Melón-Ardanaz
Created: Friday, 14 July 2023, 2:22 PM
DOP06: Deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Junmei Cairns
Created: Friday, 14 July 2023, 2:22 PM
DOP06: Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumab
Year: 2024
Source: ECCO'24 Stockholm
Authors: Chaemsupaphan, Thanaboon
Created: Tuesday, 30 April 2024, 5:03 PM
DOP06: Non-invasive identification of adherent-invasive E. coli in patients with Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Anthony Buisson
Created: Tuesday, 23 June 2020, 5:40 PM
DOP07: Long-term results of 4.5 Years of fecal microbiota transplantation for treatment of Refractory Ulcerative Colitis
Year: 2020
Source: ECCO'20 Vienna
Authors: Ahmet Uygun
Created: Tuesday, 23 June 2020, 5:40 PM
DOP07: Monitoring disease activity by intestinal ultrasound predicts biologic treatment persistence in patients with Inflammatory Bowel Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Fremberg Ilvemark, Johan
Created: Tuesday, 30 April 2024, 5:03 PM
DOP07: Targeting the canonical WNT signalling pathway as a potential novel therapy in Crohn´s associated fibrosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Annalisa Buck
Created: Friday, 14 July 2023, 2:22 PM
DOP08: A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Baldan-Martin, Montserrat
Created: Tuesday, 30 April 2024, 5:03 PM
DOP08: Cellular and molecular interaction of MAIT in mucosal tissue and their role in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Veronika Bosáková
Created: Friday, 14 July 2023, 2:22 PM
DOP08: Deep remission in paediatric Crohn’s Disease is associated with increased abundance of Dialister species and increased valerate
Year: 2020
Source: ECCO'20 Vienna
Authors: Henry Taylor
Created: Tuesday, 23 June 2020, 5:40 PM
DOP09: Eosinophils exert a pro-inflammatory role in a chronic DSS colitis model without an impact on fibrosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Inge Jacobs
Created: Friday, 14 July 2023, 2:22 PM
DOP09: Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomics
Year: 2024
Source: ECCO'24 Stockholm
Authors: Levhar, Nina
Created: Tuesday, 30 April 2024, 5:03 PM
DOP10: Early intestinal resection in Crohn’s Disease is not associated with severe long-term disease course
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nathan Grellier
Created: Friday, 14 July 2023, 2:22 PM
DOP10: Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial substudy
Year: 2020
Source: ECCO'20 Vienna
Authors: Torsten Kucharzik
Created: Tuesday, 23 June 2020, 5:40 PM
DOP10: Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Peyrin-Biroulet, Laurent
Created: Tuesday, 30 April 2024, 5:03 PM
DOP11: A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Charlotte Bache-Wiig Mathisen
Created: Friday, 14 July 2023, 2:22 PM
DOP11: Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Jairath, Vipul
Created: Tuesday, 30 April 2024, 5:03 PM
DOP11: Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Nikolas Plevris
Created: Tuesday, 23 June 2020, 5:40 PM
DOP12: Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Vermeire, Séverine
Created: Tuesday, 30 April 2024, 5:03 PM